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AbstrACt
Objective Anaemia is common among people living with 
HIV (PLWH) and has been associated with certain, often 
older, antiretroviral medications. Information on current 
antiretroviral therapy (ART) and anaemia is limited. The 
objective was to compare the associations between 
anaemia incidence or haemoglobin change with core ART 
classes in the current ART era.
Design Retrospective cohort study.
setting USA- based prospective clinical cohort of PLWH 
aged 18 and above receiving care at eight sites between 
January 2010 and March 2018.
Participants 16 505 PLWH were included in this study.
Main outcome measures Anaemia risk and haemoglobin 
change were estimated among PLWH for person- time 
on a protease inhibitor (PI) or an integrase strand 
transfer inhibitor (INSTI)- based regimen, relative to a 
non- nucleoside reverse transcriptase inhibitor (NNRTI)- 
based reference. We also examined PLWH on regimens 
containing multiple core classes. Cox proportional hazards 
regression analyses were conducted to measure the 
associations between time- updated ART classes and 
incident anaemia or severe anaemia. Linear mixed effects 
models were used to examine the relationships between 
ART classes and haemoglobin change.
results During a median of 4.9 years of follow- up, 1040 
developed anaemia and 488 developed severe anaemia. 
Compared with NNRTI use, INSTI- based regimens were 
associated with an increased risk of anaemia (adjusted HR 
(aHR) 1.26, 95% CI 1.00 to 1.58) and severe anaemia (aHR 
1.51, 95% CI 1.07 to 2.11) and a decrease in haemoglobin 
level. Time on multiple core classes was also associated 
with increased anaemia risk (aHR 1.39, 95% CI 1.13 to 
1.70), while no associations were found for PI use.
Conclusion These findings suggest INSTI use may 
increase the risk of anaemia. If confirmed, screening for 
anaemia development in users of INSTIs may be beneficial. 
Further research into the underlying mechanisms is 
warranted.
IntrODuCtIOn
Anaemia and severe anaemia are common 
among people living with HIV (PLWH).1 The 
prevalence of anaemia is elevated in PLWH 
compared with the general population. One 
study reported that among non- pregnant 
American women living with HIV, the prev-
alence of anaemia was 28.1% compared with 
15.1% among women without HIV.2 Esti-
mates vary by age, sex, HIV disease stage, use 
of antiretroviral therapy (ART) and injection 
drug use status.1 3 Among PLWH, associa-
tions have been found between anaemia and 
mortality,4–9 health- related quality of life,1 
morbidity, dementia10 and ART failure.11 In 
addition, anaemia is an independent prog-
nostic indicator associated with HIV disease 
progression,1 12 13 including development of 
AIDS.7
Research shows that ART impacts anaemia 
risk among PLWH. In the early treatment era, 
use of zidovudine (AZT) was a cause of bone 
marrow suppression leading to anaemia.14 
strengths and limitations of this study
 ► This study used a large and geographically diverse 
population of people living with HIV in care across 
the USA.
 ► This study leveraged comprehensive clinical data, 
including information on diagnoses, medication use, 
laboratory test results, demographic information 
and medical history.
 ► This study investigated the associations between 
specific types of antiretroviral therapy core regi-
mens and anaemia risk.
 ► This observational study is subject to residual 
confounding.
 ► This study focused on anaemia assessed from hae-
moglobin lab values taken at regular medical care 
visits without excluding participants with conditions 
strongly associated with haemoglobin level through 
mechanisms unrelated to HIV infection.
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Figure 1 Flow chart of inclusion/exclusion criteria for 22 027 
PLWH in care at CNICS after January 2010. Exclusions were 
made for those not exposed to any of the ART core classes, 
those with fewer than two haemoglobin levels and those 
missing baseline covariates, resulting in 16 505 PLWH who 
were included in these analyses. ART, antiretroviral therapy; 
CNICS, Centers for AIDS Research Network of Integrated 
Clinical Systems; PLWH, people living with HIV.
However, in recent years, AZT use has decreased substan-
tially as other, better tolerated ART medications have 
become available. Despite the impact of specific agents 
such as AZT, ART use in general is associated with reduced 
anaemia incidence,15 16 likely due to inhibition of HIV 
disease progression.17 Current ART regimens typically 
include a pair of nucleoside reverse transcriptase inhibi-
tors (NRTIs) as a backbone plus a core agent. Common 
core classes include non- nucleoside reverse transcriptase 
inhibitors (NNRTIs), integrase strand transfer inhibitors 
(INSTIs) and protease inhibitors (PIs). While ART use 
overall reduces anaemia, little is known about whether 
anaemia risk differs between commonly used ART classes 
in the current treatment era, particularly the newer INSTI 
class. From clinical safety data of trials, 36%–49% of partic-
ipants using PIs had haemoglobin (Hb) levels <10 g/dL, 
indicating anaemia,18 and in a randomised controlled trial 
two participants discontinued INSTI use due to anaemia 
adverse events.19 However, many studies included few 
participants or were mostly from an earlier ART era when 
older ART medications were predominantly used or from 
trials that may be less generalisable to the diverse popula-
tion of PLWH in clinical care. The objective of this study 
was to compare the rates of anaemia and severe anaemia 
development as well as changes in Hb over time based on 
classes of ART used in the current treatment era.
MethODs
Overview and setting
The present study included PLWH in care in the 
Centers for AIDS Research Network of Integrated Clin-
ical Systems (CNICS) cohort during the period from 1 
January 2010 to 31 March 2018 (the date through which 
each site had complete data (administrative censor date) 
varied somewhat, median date: 31 October 2017). The 
CNICS cohort has been described in detail elsewhere.20 
Briefly, CNICS is a dynamic prospective clinical cohort 
of >32 000 adult PLWH receiving care at eight partici-
pating sites across the USA. Comprehensive clinical data, 
including diagnoses, ART and other medications, labora-
tory test results, demographic information, and historical 
information, including ART use before enrolment, are 
collected through electronic medical records and other 
institutional data systems at each site and harmonised in 
the CNICS data repository. Medication data including 
ART use are entered into the electronic medical records 
by clinicians, or prescription fill/refill data are uploaded 
directly from pharmacy systems and verified through 
medical record review. Participants entered the current 
study on 1 January 2010 or the earliest date after 1 
January 2010 that they met the following enrolment 
criteria (cohort entry date): (1) enrolment in CNICS 
for ≥6 months to allow time for covariate ascertainment 
and (2) use of an ART regimen containing a backbone 
of two NRTIs plus a PI, NNRTI or INSTI. In addition, all 
participants were required to have at least two available 
Hb lab values during the study follow- up. Figure 1 shows 
the inclusion criteria and the exclusions made. Informed 
consent was obtained from all participants.
exposure
The exposure of interest was the ART core drug class 
(NNRTI, INSTI or PI) prescribed as part of an ART 
regimen (a backbone of two NRTIs plus a core drug). 
Participants switching to different core drugs within the 
same class were considered to be continually exposed 
to the same core drug class. Individuals with a gap of 6 
or more months in use of the ART core drug classes of 
interest were censored at the start of the gap and did not 
re- enter the study.
Person- time on INSTI or PI- based regimens was 
compared with the NNRTI reference. In addition, some 
PLWH in this cohort had prescriptions for multiple 
core classes simultaneously. Participants with regimens 
containing more than one core class were categorised 
separately in analyses as users of ‘multiple core classes’. 
Boosting agents (eg, boosted ritonavir or cobicistat) were 
not considered a second core agent.
Outcome ascertainment
Hb levels, expressed in grams per decilitre, were ascer-
tained using inpatient and outpatient laboratory data 
obtained as part of clinical care. Outcomes included 
incident anaemia (first postbaseline Hb measure below 
10 g/dL), incident severe anaemia (first postbaseline 
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Hb measure below 7.5 g/dL)21 and changes in Hb level. 
Another outcome, chronic anaemia, defined as anaemia 
lasting for ≥6 months, was also examined. Chronic 
anaemia was defined as postbaseline Hb lab results on 
two separate occasions at least 6 months apart which were 
consistently in the anaemic range without any Hb values 
above the anaemia range during this 6- month period.
Participant characteristics
Characteristics that were analysed as confounders of 
the association between ART core drugs and incident 
anaemia, severe anaemia or change in Hb over time 
included age, sex, race/ethnicity, CNICS site, hepatitis 
C virus (HCV) coinfection defined as a detectable HCV 
RNA level or HCV genotype or HCV antibody, kidney 
function measured using estimated glomerular filtra-
tion rate (eGFR; categorised as <30, 30–59 or ≥60 mL/
min/1.73 m2),22 CD4 count (categorised as ≥500, 
350–499, 200–399, 100–199 or <100 cells/mm3), viral load 
(VL, assessed as log10(VL+1)), baseline Hb (in incident 
anaemia, severe anaemia and chronic anaemia analyses 
only), and time in care at CNICS sites, defined as time 
from cohort entry date until the last available CNICS 
activity: either last lab date or last visit. HCV, eGFR, CD4 
count and VL were assessed as part of clinical care visits 
and were time- updated as repeated measures occurred. 
All covariates were selected a priori, based on review of 
the literature and clinical knowledge. In addition, assess-
ment of self- reported ART adherence was available for a 
subset of ~55% of the study population who were in care 
after each individual site initiated a clinical assessment of 
patient- reported outcomes, including adherence.23
statistical analysis
Baseline characteristics are presented for all participants 
at the cohort entry date. Median and IQR are displayed 
for continuous variables, and frequencies and propor-
tions are displayed for categorical variables.
Two multivariable Cox proportional hazards regression 
analyses were conducted, one among the subset of PLWH 
who were anaemia- free at baseline to determine associ-
ations between time- updated NNRTI, PI and INSTI use 
and development of anaemia, and another among the 
subset of participants who were free of severe anaemia at 
baseline to determine associations between time- updated 
NNRTI, PI and INSTI use and development of severe 
anaemia.
Participants were censored at (1) the time they devel-
oped the outcome of interest, (2) at the time of last 
activity in CNICS, (3) at the time of death, (4) at the 
date of administrative censoring at each site or (5) at the 
time they no longer were prescribed one of the ART core 
classes of interest, whichever came first. The timescale for 
the models was time since cohort entry. Complete case 
analysis methods were used (<2% had missing data).
In a sensitivity analysis, we examined those who were 
ART- naïve at baseline and who initiated a regimen, 
including one of the core ART classes of interest during 
study follow- up. Follow- up in this analysis began when a 
person began their initial ART regimen and extended 
until the earliest time of anaemia occurrence, last activity 
in CNICS, time of death, administrative censoring or at 
the time their initial regimen ended. PI or INSTI use was 
compared with the reference, NNRTI use. We also exam-
ined the change in Hb over time using mixed models 
among this ART- naïve population. We also conducted 
sensitivity analyses including time- updated NRTI back-
bone regimen adjustment in analyses of incident anaemia 
and incident severe anaemia risk. These sensitivity anal-
yses addressed possible concerns that the NRTI backbone 
may influence anaemia risk rather than the core agent. 
Finally, we conducted a sensitivity analysis that excluded 
users of AZT from comparisons of NNRTI, PI and INSTI 
use versus the referent category of NNRTI use because 
of concerns that AZT has been found strongly associated 
with anaemia.
Linear mixed effects models with random slopes for 
time were used to examine the association of ART core 
classes with Hb levels among all PLWH after adjustment 
for the same characteristics as in the incident anaemia 
and severe anaemia analyses. Mixed effects models use 
random slopes and intercepts at the participant level 
to handle irregular patterns of repeated measures over 
follow- up.24 All analyses were performed using Stata 
V.14.2.
Patient and public involvement
There was no patient or public participation in the 
present study.
results
In total, 16 505 PLWH met the inclusion criteria and were 
included in these analyses (figure 1). Participants had an 
average of 11 outpatient Hb values measured during a 
median follow- up of 4.9 (IQR 3.0–7.2) years. A total of 
12 626 (76%) were free of anaemia at baseline, and 15 357 
(93%) were free of severe anaemia at baseline. Table 1 
provides the baseline characteristics of the study partic-
ipants in the analyses of incident anaemia and incident 
severe anaemia. Overall, the mean age of study partici-
pants was 46 years at cohort entry, 20% were female and 
19% were coinfected with HCV. At baseline, 18% were 
prescribed regimens with an NNRTI, 53% with a PI, 
14% an INSTI and 16% regimens with multiple cores. 
INSTIs were increasingly used over the last few years of 
the study period (figure 2), and among those simultane-
ously prescribed multiple core medications the propor-
tion comprising INSTI plus another core class increased 
as study years progressed. In the analytic study sample, 
backbone regimens mainly consisted of emtricitabine/
lamivudine (3TC) plus tenofovir or 3TC plus abacavir 
(online supplementary table 1).
The overall incidence of anaemia was 2.1 per 100 person- 
years, and the overall incidence of severe anaemia was 0.8 
per 100 person- years. The unadjusted incidence rates of 
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Table 1 Baseline characteristics of PLWH in CNICS who were receiving an ART core agent of interest (n=16 505)*
Incident anaemia analysis (n=12 626) Incident severe anaemia analysis (n=15 357)
Do not develop 
anaemia (n=11 586)
Develop anaemia 
(n=1040)
Do not develop severe 
anaemia (n=14 869)
Develop severe 
anaemia (n=488)
Age, median (IQR) 45 (37–51) 47 (40–54) 45 (37–52) 46 (39–54)
Female 1574 (14) 276 (27) 2681 (18) 158 (32)
Race/ethnicity
  White 5782 (50) 396 (38) 6840 (46) 157 (32)
  Black 3720 (32) 499 (48) 5442 (37) 254 (52)
  Hispanic 1537 (13) 106 (10) 1920 (13) 58 (12)
  Other/missing 547 (5) 39 (4) 667 (4) 19 (4)
Years in CNICS at cohort entry*, 
median (IQR)
5.2 (2.3–8.8) 5.8 (2.4–9.5) 5.5 (2.4–9.0) 5.5 (2.8–9.1)
Viral load ≥400 copies/mL 2441 (21) 283 (27) 3259 (22) 172 (35)
CD4 count (cells/mm3)
  <100 528 (5) 112 (11) 915 (6) 90 (19)
  100–199 870 (8) 96 (9) 1256 (8) 63 (13)
  200–349 1974 (17) 216 (21) 2675 (18) 113 (23)
  350–499 2497 (21) 226 (22) 3160 (21) 80 (16)
  ≥500 5717 (49) 390 (38) 6863 (46) 142 (29)
Hepatitis C virus coinfection 1816 (16) 303 (29) 2711 (18) 139 (28)
Kidney function (eGFR) (mL/min/1.73 m2)
  <30 32 (<1) 36 (3) 142 (1) 42 (9)
  30–59 459 (4) 80 (8) 731 (5) 51 (10)
  ≥60 11 095 (96) 924 (89) 13 996 (94) 395 (81)
Baseline haemoglobin (g/dL), 
median (IQR)
14.5 (13.5–15.4) 13.3 (12.2–14.4) 14.3 (13.1–15.2) 12.4 (10.8–13.8)
BMI (kg/m2)
  <18.5 229 (2) 36 (3) 377 (3) 30 (6)
  18.5 to <25.0 4806 (41) 426 (41) 6120 (41) 211 (43)
  25.0 to <30.0 3929 (34) 301 (29) 4885 (33) 117 (24)
  ≥30.0 2622 (23) 277 (27) 3487 (23) 130 (27)
ART core class
  NNRTI 2109 (18) 177 (17) 2633 (18) 70 (14)
  PI 6135 (53) 558 (54) 7935 (53) 251 (51)
  INSTI 1803 (16) 93 (9) 2126 (14) 46 (9)
  Multiple core classes 1539 (13) 212 (20) 2175 (15) 121 (25)
Self- reported adherence (on a 
100- point scale), median (IQR)†
98 (93–100) 98 (91–99) 98 (92–100) 97 (90–99)
*Cohort entry date was defined as the earliest date during 1 January 2010–31 March 2018 that a person had ≥6 months in CNICS and was 
receiving an ART regimen with a core agent of interest.
†For the 55% of the population who reported medication adherence.
ART, antiretroviral therapy; BMI, body mass index; CNICS, Centers for AIDS Research Network of Integrated Clinical Systems; eGFR, 
estimated glomerular filtration rate; INSTI, integrase strand transfer inhibitor; NNRTI, non- nucleoside reverse transcriptase inhibitor; PI, 
protease inhibitor; PLWH, people living with HIV.
anaemia and severe anaemia based on ART core class are 
provided in table 2. In adjusted analyses, INSTI use was 
associated with an increased risk of anaemia (adjusted HR 
(aHR) 1.26, 95% CI 1.00 to 1.58) compared with NNRTIs 
(table 3). Use of multiple core classes together was also 
associated with an increased risk of anaemia (aHR 1.39, 
95% CI 1.13 to 1.70), while no associations were found 
between PI use and anaemia (aHR of 1.09, 95% CI 0.90 to 
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Table 2 Incidence rate of anaemia (haemoglobin <10 g/dL) 
and severe anaemia (haemoglobin <7.5 g/dL) by ART core 
drug class
ART 
regimen
Follow- up time 
(person- years) Events
Rate (per 100 
person- years)
Anaemia
  NNRTI 9964 150 1.50
  PI 24 710 485 1.96
  INSTI 7389 155 2.10
  Multiple 
core 
classes
8172 250 3.06
Severe 
anaemia
  NNRTI 12 113 57 0.47
  PI 31 156 204 0.65
  INSTI 9132 84 0.92
  Multiple 
core 
classes
11 258 143 1.27
ART, antiretroviral therapy; INSTI, integrase strand transfer 
inhibitor; NNRTI, non- nucleoside reverse transcriptase inhibitor; PI, 
protease inhibitor. Ta
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Figure 2 Proportion of study population (n=16 505) using 
various ART classes during complete years of study follow- 
up. This figure shows the trends in use of the ART core 
classes during 2010–2017. ART, antiretroviral therapy; INSTI, 
integrase strand transfer inhibitor; NNRTI, non- nucleoside 
reverse transcriptase inhibitor; PI, protease inhibitor.
1.32). In adjusted analyses restricted to participants free 
of severe anaemia at baseline (table 3), INSTI use was 
associated with an increased risk of severe anaemia (aHR 
1.51, 95% CI 1.07 to 2.11) compared with NNRTI use. 
Although the HR appeared elevated, there was no asso-
ciation between time on multiple ART core classes and 
an increased risk of severe anaemia (aHR 1.30, 95% CI 
0.95 to 1.78), and no association was found for PIs (aHR 
1.09, 95% CI 0.81 to 1.47). Among the 12 626 PLWH who 
were free of anaemia at baseline, 225 developed chronic 
anaemia (lasting for ≥6 months) during follow- up. For 
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Table 4 Association of ART core classes with change in 
haemoglobin level during follow- up in adjusted analyses 
(linear mixed effect model) (n=16 505)
ART class Coefficient* 95% CI P value
NNRTI (reference)
  PI −0.01 −0.04 to 0.03 0.675
  INSTI −0.06 −0.10 to -0.03 <0.001
  Multiple core 
classes
−0.14 −0.18 to -0.11 <0.001
*Coefficient is the mean difference per year in haemoglobin (g/
dL) for each core regimen relative to the NNRTI core regimen, 
after adjustment for site, age, sex, race/ethnicity, hepatitis C virus 
coinfection, CD4 cell count, viral load, eGFR and years in study.
ART, antiretroviral therapy; eGFR, estimated glomerular filtration 
rate; INSTI, integrase strand transfer inhibitor; NNRTI, non- 
nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
chronic anaemia, results were similar to those in the 
primary analysis, although CIs overlapped 1. Relative to 
NNRTI use, person- time on multiple core classes was asso-
ciated with an aHR for chronic anaemia of 2.21 (95% CI 
0.94 to 5.18), person- time on an INSTI with an aHR of 
1.90 (95% CI 0.76 to 4.64) and person- time on a PI with 
an aHR of 1.27 (95% CI 0.54 to 3.04).
Average Hb levels remained steady during follow- up; 
the mean level was 14.1 g/dL (IQR 12.7–15.1) at base-
line and 14.0 g/dL (IQR 12.6–15.2) at the last available 
measurement per person. Relative to NNRTI use, a 
decrease in Hb level over time was associated with both 
INSTI use (−0.06 g/dL per year, 95% CI −0.10 to 0.03) 
and use of multiple core classes (−0.14, 95% CI −0.18 to 
0.11). No association was found for PI use (−0.01, 95% CI 
−0.04 to 0.03) (table 4).
The sensitivity analysis restricted to ART- naïve partic-
ipants included 6426 PLWH who were free of prevalent 
anaemia at baseline, of whom 378 developed anaemia. 
Compared with NNRTI initiators, those initiating a PI 
had an aHR of 0.69 (95% CI 0.45 to 1.06) while those 
initiating an INSTI had an aHR of 1.10 (95% CI 0.84 
to 1.44) (online supplementary table 2). The mixed 
model examining change in Hb over time among ART- 
naïve PLWH initiating one of the ART core classes of 
interest included 7264 participants. Compared with 
NNRTI initiators, a decrease in Hb was found for PI 
use (−0.08 g/dL per year, 95% CI −0.16 to 0.01), while 
INSTI use was associated with a larger decrease in Hb 
level over time (−0.15 g/dL per year, 95% CI −0.22 to 
0.09) (online supplementary table 3). Results from the 
sensitivity analyses including time- updated NRTI back-
bone regimen adjustment were essentially unchanged 
(online supplementary table 4). Finally, results from 
the sensitivity analysis excluding participants with AZT 
use indicated similar findings to those from the primary 
analyses, although CIs were wider (online supplemen-
tary tables 5 and 6).
DIsCussIOn
In this study of 16 505 PLWH in care within the USA in the 
current treatment era (2010 and after), we observed that 
INSTI use and time on multiple core ART classes were 
associated with decreases in Hb levels during follow- up 
compared with using NNRTI- based regimens. We found 
that INSTI use was associated with an increased risk of 
anaemia (aHR 1.26, 95% CI 1.00 to 1.58) and severe 
anaemia (aHR 1.51, 95% CI 1.07 to 2.11) as well as a 
decrease in Hb levels over time. Furthermore, the naïve 
user analysis indicated similar findings despite a smaller 
sample size. These findings could have implications for 
the treatment approach that should be used in people 
with risk factors for anaemia.
This study’s strengths include its large and geographi-
cally diverse study population and longitudinal data struc-
ture. Nevertheless, there are limitations to this study to 
consider, including the observational nature of the data, 
which may be subject to residual confounding, including 
confounding by indication.25 However, anaemia is not a 
recognised adverse effect of NNRTIs, PIs or INSTIs. Thus, 
it is unlikely that ART core class was selected based on 
prescriber concern about anaemia risk. Additionally, we 
did not exclude participants with conditions strongly 
associated with anaemia or Hb level, including those on 
dialysis, receiving erythropoietin or with severe bleeding, 
which likely caused some of the anaemia cases in this 
analysis. However, in the sensitivity analysis focusing on 
factors associated with chronic anaemia (less likely due 
to bleeding), findings for INSTI versus NNRTI core 
regimens were similar to those including all PLWH who 
became anaemic. Information on ART medication use 
was from prescription data, which does not necessarily 
indicate medications were taken, although self- reported 
adherence was high (~98%) in the subset for whom 
adherence information was available. CNICS participants 
who provided adherence information have been shown 
to be representative of the overall population of PLWH in 
CNICS.23 26 Finally, the fact that this study was conducted 
among PLWH in care in the USA who are on ART may 
limit the generalisability of findings to PLWH who live 
outside of the USA.
There have been few epidemiological studies of 
anaemia risk among users of newer ART core regimens. 
From clinical safety data reported from multiple trials, 
approximately 36%–49% of participants using PIs had 
Hb levels <10 g/dL, indicating anaemia,18 and in another 
trial two participants discontinued INSTI use due to 
anaemia adverse events19; however, the strict inclusion 
criteria applied in clinical trials makes it difficult to 
generalise these findings to more diverse populations of 
PLWH in clinical care. Another study, conducted during 
the newer era of HIV treatment with drugs other than 
AZT (during 2008–2012), presented findings for AZT 
versus non- AZT regimens, finding an increased risk of 
anaemia among AZT compared with non- AZT regimens 
(HR=2.84, 95% CI 1.52 to 5.31).27 However, anaemia risk 
was not analysed separately for the use of specific classes 
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of ART, resulting in the inability of comparison with the 
present study’s findings and a lack of generalisability to 
PLWH who are treated with newer ART core agents.
It is possible that PLWH in our study whose HIV is 
progressing due to resistance or other complications 
may get switched to an INSTI. This, in addition to prior 
knowledge that poorly controlled HIV parameters are on 
their own a risk factor for anaemia,5 28 29 could result in 
confounding by indication. However, the switch to INSTI 
core regimens since their approval in 2007 has been 
widespread in this population (figure 2) and INSTIs are 
recommended for use as initial regimens.30 In addition, 
we rigorously controlled for many of the important HIV- 
related factors that correspond to poorly controlled HIV, 
and our sensitivity analysis examining PLWH initiating 
their initial regimen failed to reinforce the notion that 
an increased risk of anaemia among INSTI core regimen 
users could be entirely explained by sicker participants 
getting switched to these therapies.
PLWH on multiple core classes were in a different 
category in our analyses. There are several reasons 
PLWH may be prescribed multiple core classes. For 
example, sometimes PLWH are prescribed multiple core 
classes to ensure they receive a complete regimen while 
awaiting approval for specific agents from their insur-
ance company. However, the primary concern was that 
they were receiving multiple core classes due to provider 
concerns such as prior failed regimens, which may also 
increase their risk of anaemia.
In conclusion, in this large, diverse, multicentre cohort 
of PLWH, we found that INSTI use and time on multiple 
ART core classes were associated with progression to 
anaemia and a lower Hb level. INSTI use was also associ-
ated with severe anaemia risk. Our findings suggest that 
careful selection of ART regimen could mitigate anaemia 
development, although this anaemia risk needs to be 
balanced with the possibility of improvement in overall 
HIV care.31 Further research is needed to replicate the 
finding of INSTI core regimen use and anaemia risk and 
to understand the underlying mechanisms. If confirmed, 
screening for anaemia development in users of INSTIs 
may be beneficial.
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